A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

Clinical trial NCT00250354 · COMPLETED

Trial details

NCT number: NCT00250354
Sponsor: Janssen Pharmaceutica N.V., Belgium
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Conduct Disorder Oppositional Defiant Disorder Disruptive Behavior Disorder

Start date: 1997-09-01
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.